Safety study of q3w S-1 in combination with q3w trastuzumab for HER2 positive metastatic breast cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2019
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 04 Feb 2019 Status changed from recruiting to discontinued.
- 04 Jul 2013 New trial record